Marty Makary Resigns as FDA Commissioner

Marty Makary Steps Down as FDA Commissioner

Multiple news outlets are reporting that Dr. Marty Makary has resigned as Commissioner of the U.S. Food and Drug Administration after serving in the role for just over one year.

Makary, a surgeon and public health researcher, became FDA Commissioner in 2025 and oversaw a period of significant agency activity involving drug review modernization, food policy initiatives, artificial intelligence integration, and tobacco enforcement policy.

Reports indicate that Kyle Diamantas is expected to serve as acting commissioner while the administration considers a permanent replacement.

Regulatory Areas Impacted During His Tenure

During Makary’s leadership, FDA advanced several notable initiatives, including:

• Expanded use of AI tools within FDA operations
• Updated approaches to biosimilars and drug review timelines
• Increased focus on food ingredient and additive oversight
• Ongoing tobacco and ENDS enforcement policy developments
• New inspection and compliance modernization initiatives

What Industry Should Watch

Leadership transitions at FDA can influence:

• Regulatory priorities and enforcement focus
• Guidance development timelines
• Inspection and compliance initiatives
• Drug, food, tobacco, and biologics policy direction

At this stage, FDA has not announced broader operational changes related to the transition.

EAS Perspective

Changes in FDA leadership often create questions regarding regulatory continuity and future policy direction. Companies operating in FDA-regulated industries should continue monitoring agency announcements and emerging priorities in the coming months.

EAS will continue tracking developments related to FDA leadership and regulatory policy.